Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis

NCT00606450 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: CC-10004
DRUG: CC-10004
DRUG: Placebo

Sponsor

Amgen